Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Lofexidine Granules vs Tablets and Food Effect
NCT04188730Phase 1Completed
- Sponsor
- US WorldMeds
- Start
- Feb 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lofexidine in opioid withdrawal syndrome (OWS) (3 arms), sponsored by US WorldMeds. Primary endpoints: Mean Maximum Plasma Concentration at Day 3, Time to Maximum Plasma Concentration at Day 3 and 4 more. Started Feb 2021; status: completed.
02
Drugs
lofexidine
03
Conditions
opioid withdrawal syndrome (OWS)
Beyond the preview
Go deeper on NCT04188730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188730.